definiens: shall mean direct out - of - pocket costs and Zealand i nternal personnel costs calculated at the Adjusted Zealand FTE Rate ; in eac h case to the extent : ( i ) recorded as an expense in accordance with IFRS by Z ealand after ZP Nomination ; and ( ii ) in connection with tasks that are specifically identified or reasonably allocable to the development of a given Therapeutic Peptide or Product . Such costs may include those arising from pre - clinical activities, clinical trials, preparation filing and prosecution of marketing authorisations, but shall not include costs for pre - Launch, Launch or other commercial activities, or any costs paid to Third Party Licens ors . Reimbursable Costs shall not include any costs to the extent already r eimbursed to Zealand by any Third Party, including from grants or under any Par tnering Arrangement, or reimbursed under the Co - Financing Option, or any pa yments made by Zealand to Protagonist under this Agreement . Reimbu rsable Costs shall not include expenses that are not primarily associated with pre - clinical development or development functions, including sal aries and benefits of executive officers ( unless primarily involved in pr e - clinical development or development activities ), administrative support for such officers, and all costs of the finance, purchasing, legal ( including both i n - house and outside counsel ), business development and corporate d evelopment functions